Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women

Abstract

The quadrivalent HPV vaccine targeted at types 6, 11, 16, and 18 was safe and immunogenic in HIV-infected women aged 13-45 years. Women with HIV RNA load >10 000 copies/mL and/or CD4 count <200 cells/µL had lower rates of seroconversion rates. Clinical Trials Registration. NCT00604175.

A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men

“…The titers plateau at lower levels than seen in HIV-uninfected populations or HIV-infected children [12], [14]. We have demonstrated a rapid increase in titers four weeks after a delayed fourth dose of qHPV vaccine consistent with an anamnestic response as has been described in other populations [13], [14].…”

“…While the qHPV vaccine series is highly immunogenic in HIV-infected adults and children, antibody titers are lower than those reported in HIV-uninfected populations [10], [11], [12]. In studies of both HIV infected and HIV-uninfected vaccine recipients, the titers developed in response to the standard three-dose qHPV series peak soon after the third dose then decline.…”

Vaccinal Prevention of the Diseases Caused by Human Papillomavirus: Evidence-Based Medicine. Review of Clinical Guidelines

“…В настоящее время накоплены результаты клини-ческих исследований у пациентов разных возрастов и полов, страдающих ВИЧ-инфекцией, которые проде-монстрировали высокий уровень безопасности и имму-ногенности квадривалентной вакцины [61][62][63][64].…”

Immunization of HIV-infected adult patients — French recommendations

“…85 The ACTG A5240 study was carried out on women aged 13 to 45 years who were stratified according to CD4 count and showed that the quadrivalent vaccine was well tolerated and resulted in high seroconversion rates; immunogenicity was lower in women with CD4 lymphocyte counts <200/mm 3 or a HIV viral load > 10 000 copies/mL. 86 In the HPV-020 study carried out in South Africa, 22 non-HIV-infected women and 42 HIV-infected women (WHO clinical stage 1) received the bivalent vaccine. All female subjects were seropositive for HPV 16 and 18 a month after the third dose (M7) on the ELISA test.…”